👉GTBP is TODAY’S #1 ALERT 👈

Hey there, Folks, Jeff Bishop here.

Stocks are down and bond yields are up today after Moody’s stripped the U.S. of its triple-A credit rating. 

The yield on the 30-year treasury has crossed 5.0% for the first time since January and come within 10 basis points of its high over the past decade.

Personally, I think investors were looking for an excuse to give up some of the recent, historic rally…

The fact is, Standard & Poor’s and Fitch Ratings — the other two “Big Three” major credit rating agencies — downgraded U.S. debt to AA+ years ago. Moody’s is just catching up.

Regardless, there will be a good amount of selling pressure today, so I’ve tracked down some trade ideas I think could defy the broader markets.

At the top of my list is GT Biopharma, Inc. (GTBP).

If you take a look at its chart, you’ll see it’s sitting at a support level that’s been pretty solid so far in 2025, just above the $2.20 level.

At the same time, the stock’s 50-day moving average has been above this level since the start of March. That tells me there’s plenty of upside here.

But it’s the news the company just dropped this morning that has me most dialed into the stock right now.

Just moments ago, GTBP released some HUGE news (read it here)

The fact that the company is now moving its Phase 1 trial to the second cohort is a major milestone for GTBP and its investors.

With biotechs, you always hold your breath as things progress with FDA trials because things could come to a halt at any time if the data looks poor.

When a company gets the green light to proceed, traders should celebrate it.

I think this is an awesome piece of news today, and you should dig into your research on this stock right away – they could be in for a BIG DAY!

👉  GTBP is TODAY’S #1 ALERT 👈

GTBP is a clinical-stage biopharma company focused on developing immuno-oncology therapeutic products based on its proprietary TriKE® NK cell engager platform.

The company describes TriKE® as a “first-in-class modular immune oncology protein therapeutic” and notes that it is “not a cell therapy.”

In theory, it can be used to treat both solid tumors and hematological cancers (often referred to as “blood cancers”), and with less toxicity than cell therapies such as CAR-T.

Here are the top 5 things about the company that stand out to me…

1. TriKE® Technology: The Triple Threat in Cancer Therapy 🧪🔬

GTBP is pioneering a unique approach with its TriKE® (Tri-specific Killer Engager) platform. This technology is designed to harness the cancer-killing abilities of a patient’s natural killer (NK) cells. 

By simultaneously engaging NK cells and cancer cells, TriKE® aims to selectively kill cancer cells without harming healthy tissue. This method is particularly promising for treating cancers such as acute lymphocytic leukemia and non-Hodgkin’s lymphoma.

2. Promising Clinical Trials: GTB-3650 in the Spotlight 💉📈

On January 27, GTBP announced the dosing of the first patient in its Phase 1 trial of GTB-3650, a second-generation TriKE® therapy targeting hematologic malignancies. 

Initial data from this trial is expected later this year, and the announcement has already generated significant investor interest, with the company’s stock experiencing a notable uptick following the news.

3. Strategic Leadership: New Board Appointments 🧠👥

Last Wednesday, GTBP announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer has extensive experience in investment banking and received her MBA from the Wharton School of the University of Pennsylvania. She is the founder and Chief Investment Officer of GreenTech Research, “the very first U.S.-based sustainable fund and publisher of growth equity research and global market forecasting.”

The next day, GTBP appointed Andrew Ritter to the Board. Mr. Ritter brings over two decades of leadership experience in biotechnology and healthcare technology. His track record includes leading multiple successful exits and scaling healthcare companies.

4. Analyst Confidence: Strong Buy Ratings 📊💰

Analysts are showing confidence in GTBP’s potential. On Friday, Roth MKM reiterated its BUY rating with an $11.00 12-month price target — nearly 400% higher than the stock’s closing price that day.

Public.com says the company has four “Strong Buy” ratings and one “Buy” rating” with a consensus price target of $12.80 — nearly 500% upside.

5. Exclusive Collaboration: University of Minnesota Partnership 🤝🎓

GTBP holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using TriKE® technology.

This partnership not only provides access to cutting-edge research but also strengthens the company’s position in the competitive biotech landscape.

Bottom Line: GTBP is making waves with its innovative TriKE® technology, promising clinical trials, strategic leadership, strong analyst support, and valuable academic partnerships.

The company was sitting on $2.6 million in cash and short-term investments as of March 31, 2025, and last week, it revealed it had secured $5.45 million an additional private-placement financing.

Its stock is sitting at a pretty solid support level, and today’s news could be the trigger to launch it higher.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Also, be sure to review this investor presentation released this month and the company website.

For investors looking to tap into the future of cancer therapy, GTBP is a company worth watching. 🚀📈

To Your Success,

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Virtus Media Group for advertising GT Biopharma, Inc for a one day marketing program on May 19, 2025. It might seem obvious, but while our client claims not to own any shares in GT Biopharma, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into GT Biopharma, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.